Zobrazeno 1 - 10
of 14
pro vyhledávání: '"J. J. Croles"'
Autor:
Martin Fey, Sophie D. Fosså, Linda de Prijck, Allan T. van Oosterom, Hendrik Van Poppel, Simon Horenblas, J. J. Croles, Pieter H.M. De Mulder, Martine Van Glabbeke, Gerald H. Mickisch
Publikováno v:
Cancer. 101:533-540
BACKGROUND In patients with metastatic renal cell carcinoma (MRCC), interferon-α (IFN) monotherapy leads to response rates of 5–15%, dependent on the selection of patients. In 1995, preclinical and clinical data indicated an improvement of these r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2f7c763e2ca2c2ec4f88057c1aef2c3
https://doi.org/10.1002/cncr.20307
https://doi.org/10.1002/cncr.20307
Autor:
M.A. Lentz, A. van Oosterom, P.H.M. de Mulder, A. Svedberg, Sophie D. Fosså, R. de Wit, A. Pawinski, J. J. Croles
Publikováno v:
European Journal of Cancer, 33(3), 496-499. Elsevier Ltd.
The aim of this study was to determine the objective tumour response rate and duration of response and toxicity of linomide (Roquinimex) treatment in patients with disseminated renal cell carcinoma, pretreated or not pretreated with immunotherapy. Fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e6445d3caf6f4bc4184cb80a27ddcc5
https://doi.org/10.1016/s0959-8049(97)89028-4
https://doi.org/10.1016/s0959-8049(97)89028-4
Autor:
P. A. Van Liessum, C. J. A. Punt, Y. Kamm, J. T. M. Burghouts, J. J. Croles, P.H.M. de Mulder
Publikováno v:
Cancer, 72(7), 2107-2111. John Wiley and Sons Inc.
Background 5-Fluorouracil (5-FU), when combined with leucovorin (LV) or interferon-alpha (IFN-alpha), may result in improved response rates compared with 5-FU alone in patients with advanced colorectal cancer. The authors investigated the clinical ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c9ad947373afa5d9a14b010390d804d
https://doi.org/10.1002/1097-0142(19931001)72:7<2107::aid-cncr2820720708>3.0.co
https://doi.org/10.1002/1097-0142(19931001)72:7<2107::aid-cncr2820720708>3.0.co
Autor:
T. Skovsgaard, C.J.A. Punt, L. Hammershaimb, J. Douma, J. Schüller, J. J. Croles, J. Zhang, E. W. Muller, H. Lochs, H.J. Keizer, C. H. H. Ten Napel
Publikováno v:
Annals of Oncology, 13, 81-6
Annals of oncology, 13(1), 81-86. Oxford University Press
Annals of Oncology, 13, 1, pp. 81-6
Annals of oncology, 13(1), 81-86. Oxford University Press
Annals of Oncology, 13, 1, pp. 81-6
Item does not contain fulltext BACKGROUND: Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV). Phase II trials have shown promising activity of 5-FU/LV/TMTX in patients with advanced colorectal cancer (ACC). T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4827ac55aa0af8f3033d5953c11d28c7
http://hdl.handle.net/2066/185518
http://hdl.handle.net/2066/185518
Publikováno v:
European Journal of Cancer and Clinical Oncology. 27:755-757
The activity of cisplatin against advanced metastatic adenocarcinoma of unknown primary site (ACUP) was evaluated in 21 patients. Cisplatin (100 mg/m 2 ) was given as a 4-h continuous infusion every 3 weeks, with appropriate fluids and diuretics. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1508aad7f255810b82745b272e78de60
https://doi.org/10.1016/0277-5379(91)90182-d
https://doi.org/10.1016/0277-5379(91)90182-d
Autor:
C. P. J. Vendrik, Jan H. Schornagel, F. Ten Kate, Richard Sylvester, J. Keizer, A.T. van Oosterom, K. Vermeylen, Jean-Pierre Droz, Ted A.W. Splinter, J. J. Croles
Publikováno v:
Germ cell tumours: 3 / Jones, W.W. [edit.]
Publisher Summary This chapter presents a preliminary report of the EORTC GU-Cooperative Group Surveillance Study. The EORTC Genito-Urinary Cooperative Group decided to start a wait-and-see policy study to see if the data from the other centers could
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea94f3d52b9663ba560c8afc36926267
https://hdl.handle.net/10067/99090151162165141
https://hdl.handle.net/10067/99090151162165141
Publikováno v:
Cancer. 72(7)
5-Fluorouracil (5-FU), when combined with leucovorin (LV) or interferon-alpha (IFN-alpha), may result in improved response rates compared with 5-FU alone in patients with advanced colorectal cancer. The authors investigated the clinical efficacy of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1217c36e99e22ff876d0c489e501b029
https://pubmed.ncbi.nlm.nih.gov/8374869
https://pubmed.ncbi.nlm.nih.gov/8374869
Publikováno v:
European journal of cancer (Oxford, England : 1990). 27(6)
The activity of cisplatin against advanced metastatic adenocarcinoma of unknown primary site (ACUP) was evaluated in 21 patients. Cisplatin (100 mg/m2) was given as a 4-h continuous infusion every 3 weeks, with appropriate fluids and diuretics. The o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e0148a5f5dcad75319a252201a3cefa3
https://pubmed.ncbi.nlm.nih.gov/1829919
https://pubmed.ncbi.nlm.nih.gov/1829919
Publikováno v:
European Journal of Cancer. 29:S93
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0969fdd79a651f16deacfea4fd1ede3
https://doi.org/10.1016/0959-8049(93)91116-3
https://doi.org/10.1016/0959-8049(93)91116-3
Autor:
M. de Pauw, Sophie D. Fosså, G. Stoter, Richard Sylvester, J. J. Croles, Aldo V. Bono, W. G. Jones
Publikováno v:
World Journal of Urology. 4:182-185
In a phase II chemotherapy study, patients with metastatic prostate cancer were given mitomycin-C 15 mg/m2 i.v. q 6 weeks. A partial response rate of 29% was demonstrated in 31 fully evaluable patients with bidimensionally measurable metastatic depos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be60d6c46e561dd8838f851f005c4674
https://doi.org/10.1007/bf00327017
https://doi.org/10.1007/bf00327017